ANTI-SARS-COV-2 RECOMBINANT ANTIBODIES


ANTI-SARS-COV-2 RECOMBINANT ANTIBODIES



 Antibodies derived from patients are critical reagents in understanding SARS-CoV-2 and COVID-19. In patients who have survived COVID-19, infection elicited an effective antibody response against viral proteins. Recent studies reveal that the receptor binding domain (RBD) of SARS CoV-2 spike protein is a common antigen used by the immune system to generate neutralizing antibodies.

Recombinant genetic technology can be used to isolate and manufacture these antibodies for biomedical uses. Proteintech is partnering with Active Motif to offer an array of recombinant human antibodies against viral spike proteins. These antibodies are developed from genes isolated from B cells of COVID-19 patients. The viral spike protein specific antibody genes were isolated from patient serum, cloned, expressed in HEK293 cells and then subjected to extensive validation in ELISA, Western blotting, and neutralization assays.